All Activity

This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free. แทงบอล

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. เว็บแทงบอลออนไลน์

A Republican congresswoman is circulating draft legislation that would keep hemp THC beverages legal under federal law, creating a carve-out from the broad recriminalization of products derived from the crop that is set to take effect later this year, Marijuana Moment has learned. The Hemp-Derived Beverage Regulatory Clarity Act from Rep. Beth Van Duyne (R-TX), in its current form, would allow adults over 21 to purchase and consume hemp THC drinks with up to 5 milligrams of delta-9 THC per serving. It would also impose a federal tax of 10 cents per milligram of any hemp-derived cannabinoid contained within such beverages. Hemp drinks would be regulated by the Treasury Department’s Tax and Trade Bureau (TTB) in consultation with the Department of Health and Human Services, and TTB could set requirements for hemp beverage testing, packaging, labeling and serving and container sizes. Legal beverages could only contain naturally-occurring cannabinoids that are cultivated and processed within the U.S. “A naturally-occurring cannabinoid regulated in accordance with [the bill] shall be deemed safe and may be added to a hemp-derived beverage intended for human consumption,” the draft bill obtained by Marijuana Moment says. Manufactures, distributor, wholesales and sellers of hemp drinks would be required to obtain federal permits. Companies could not sell multi-serving containers larger than 750 milliliters under the legislation. It also directs the National Academies of Science, Engineering, and Medicine to publish a report on the safety of naturally-occurring cannabinoids and their use in beverages, while requiring TTB to issue a separate report on the proper serving sizes for hemp-derived beverages. The legislation further clarifies that states, Indian tribes and localities could set regulations that are “more stringent” than federal rules, but says that they could not prohibit the shipment or transportation of hemp beverages through their borders on the way to other jurisdictions. The draft bill has not yet been formally introduced, and its provisions could change before that happens. Staff for Van Duyne did not respond to Marijuana Moment’s request for comment for this story. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, he signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. The circulation of the new draft legislation comes as the White House is separately making it clear that Trump wants Congress to take action to amend the law that threatens to federally recriminalize hemp-derived products. The administration “welcomes the opportunity to work with the Congress to, at a minimum, update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products,” the Office of Management and Budget (OMB) said this month, “while preserving the Congress’s intent to restrict the sale of products that pose serious health risks.” The call to avert a broad prohibition on hemp CBD products was included in a statement of administration policy about an annual agriculture spending bill that passed the House of Representatives. Several lawmakers had filed amendments to that legislation to keep hemp products legal, but each was either blocked by the House Rules Committee from advancing to a floor vote or withdrawn by its sponsor. “The Administration supports advancement of this legislation, but looks forward to addressing its concerns prior to enactment,” OMB said in its statement of administration policy. “The Administration looks forward to working with the Congress to provide more input as the bill’s legislative process unfolds.” In April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump said in a Truth Social post on the same day his administration announced it is moving forward with rescheduling marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Industry advocates say that the law as enacted last year not only threatens to prohibit intoxicating and synthetic cannabinoid products but also stands to remove popular full-spectrum CBD products that many Americans use therapeutically from the market. “ONE in FIVE adults used it in the past year, and many say it improved their chronic pain enormously,” the president said in his social media post, adding that hemp-derived CBD “has made a HUGE difference for so many people.” He also referenced a new initiative the administration launched in April to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows products to have up to 3 milligrams of total THC per serving. “In December, I signed a very important Executive Order calling for Research and Innovation for Hemp-derived CBD,” Trump said. “Our wonderful Dr. Mehmet Oz moved fast to follow the directive in the Executive Order, and launched a model for some Seniors earlier this month. But more must be done!” “Please get it done, and SOON,” the president said in reference to a congressional fix for the broad recriminalization set to take effect in November. “Thank you for your attention to this matter!” It’s not clear how far Trump wants to scale back the scope of the scheduled federal restrictions on hemp products and what kinds of revised THC rules and limitations he would prefer to sign into law. Separately, White House officials recently provided a congressman’s office with feedback on hemp regulatory legislation. In April, Vince Haley, director of the White House Domestic Policy Council and James Braid, assistant to the president for legislative affairs, sent hemp policy suggestions to Rep. Andy Barr (R-KY). “We appreciate your work to advance the policy of” an executive order Trump signed in December that included provisions seeking to protect Americans’ access to CBD products, the staffers wrote in a letter to the congressman. “We are transmitting for your consideration draft legislative text and comments to address the statutory definition of final hemp-derived cannabinoid products in order to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks,” the White House officials said, according to a social media post containing a screenshot of the letter. “We are available for discussion and further technical assistance.” Separately, anti-marijuana organizations filed a lawsuit suit against the Medicare hemp CBD coverage policy—but a judge dismissed the case last month, ruling that they don’t have standing. Lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz had filed a brief asking that the case be dismissed. The White House Office of Management and Budget has also held a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. As hemp products have become more popular with consumers, some large brands are attempting to get in on action. Major retailer Target, for example, is expanding its participation in the hemp-derived THC beverage market. Last year, the company began a pilot program involving sales of cannabis drinks at 10 select stores in Minnesota. That apparently went well, and now the company has obtained licenses from Minnesota regulators to sell lower-potency hemp edible products—including THC drinks—at all 72 of its stores in the state. A U.S. Department of Agriculture report published in April shows that farmers in the U.S. grew three-quarters of a billion dollars worth of hemp crops in 2025—a 64 percent increase from the prior year. Read the full draft hemp beverage bill below: The post GOP Lawmaker Circulates Bill To Keep Hemp THC Drinks Federally Legal appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“We found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC.” By Andrea Efre, University of South Florida College of Nursing The cannabis sleep market represents a shift away from traditional pharmaceuticals toward a natural alternative. Historically, cannabis products marketed for sleep have largely focused on THC because of its sedating qualities. Dispensary recommendations, product marketing and consumer assumptions have reinforced the belief that THC is the cannabinoid most responsible for helping people sleep. But our new research, recently published in the Journal of the American Association of Nurse Practitioners, suggests it may be time to rethink that assumption. After conducting a systematic review and meta-analysis of medical cannabis for insomnia, we found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC. Across the available evidence, medical cannabis was associated with reduced sleep disturbance, increased total sleep time and less daytime sleepiness. Yet THC-containing formulations did not demonstrate significant improvements in sleep outcomes and were associated with higher rates of adverse effects. This finding matters because nearly one in four Americans reports using cannabis to improve sleep, while more than one-third of adults fail to obtain adequate sleep on a regular basis. Faced with insomnia, limited access to behavioral therapies and concerns about conventional sleep medications, millions of consumers are turning to cannabis and often relying on marketing claims, online forums and anecdotal experiences rather than clinical evidence to guide their decisions. To better understand what the science actually shows, we reviewed nearly 4,600 studies and identified 18 that met rigorous inclusion criteria, with seven eligible for meta-analysis. These studies evaluated CBD, CBN, THC and cannabinoid combinations administered as capsules, oils, tinctures and sublingual preparations. Compared with placebo, medical cannabis was associated with meaningful improvements in sleep disturbance, total sleep time and daytime sleepiness. Adverse effects were generally mild to moderate and most commonly included drowsiness, dry mouth, dizziness and gastrointestinal symptoms. CBD and CBN consistently demonstrated the most promising results. CBD doses ranging from 50 to 300 milligrams and CBN doses ranging from 20 to 100 milligrams were associated with the most consistent improvements in sleep quality and duration. Lower-dose CBD products, particularly those containing less than 50 milligrams, generally showed little benefit unless combined with CBN. This finding raises an uncomfortable question for the rapidly expanding sleep-products marketplace. Many commercially available CBD sleep products contain doses substantially lower than those evaluated in clinical studies. Consumers may assume that because a product contains CBD and is marketed for sleep, it reflects the available evidence. In many cases, that assumption may be wrong. THC performed differently. Despite its reputation as the cannabinoid most associated with sleep, THC-containing formulations produced mixed results and were associated with higher rates of adverse effects, while CBD- and CBN-focused formulations demonstrated more consistent benefits across studies. This does not mean THC has no role in sleep management, but it does suggest that its reputation as the primary sleep-promoting cannabinoid may be stronger than the evidence supporting it. For decades, the public conversation surrounding cannabis and sleep has focused primarily on THC. Meanwhile, CBD and CBN—two cannabinoids that showed greater promise in the available evidence—have received comparatively less attention. If clinicians, researchers, manufacturers and consumers are genuinely interested in improving sleep outcomes, future conversations should be driven by evidence rather than assumptions. The evidence suggests cannabinoids are generally well tolerated when appropriately dosed and monitored, but informed use still matters. Like many therapeutic agents, cannabinoids can interact with prescription medications and potentially alter drug concentrations. People taking blood thinners, cardiovascular medications, psychiatric medications or multiple prescription drugs should talk with their healthcare provider about potential interactions before adding cannabinoid products to their routine. More research is needed, particularly larger and longer-term clinical trials using standardized formulations and dosing protocols. Yet the evidence is already strong enough to challenge one of the most common assumptions in cannabis medicine. For years, consumers have been told that THC is the cannabinoid most closely linked to sleep. Our review suggests the science is telling a different story. If the goal is truly evidence-based cannabis medicine, the future of sleep therapy may depend not on asking whether cannabis works, but on identifying which cannabinoids work best. Dr. Andrea Efre is an associate professor at the University of South Florida College of Nursing and a nurse practitioner with over a decade of experience speaking to nurses and healthcare professionals about cannabis. She and her colleagues recently completed a systematic review and meta-analysis examining the impact of medical cannabis on insomnia. From their work they developed a clinical resource for healthcare providers and are sharing their work throughout health communities. The post Our New Study Shows That The Science Of Cannabis And Sleep Extends Beyond THC (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A California Republican senator says it is time to have a “serious discussion” about putting a measure on the ballot to potentially “reverse” legalization of marijuana in the state—also raising concerns about President Donald Trump’s move to reschedule cannabis at the federal level. “I think it’s time to assess the effects, the significant unintended consequences of the legalization of marijuana, which has not just happened in California, but in other states too,” Sen. Roger Niello (R) said at a hearing of the Senate Business, Professions and Economic Development Committee last week. “Now we can’t change it without going back to the people, but I think we should have a serious discussion, a serious analysis of the obvious…unintended negative consequences I don’t think that the writers of the proposition cared about,” he said as first reported by State Affairs, referring to the cannabis legalization ballot initiative that California voters approved in 2016. “I think these could have been predicted. They just wanted recreational use to be legalized.” Niello raised concerns that “we’re even seeing our current president now advocating that by downplaying the classification of marijuana at the federal level.” “We have seen significant negative consequences of this legalization, both here as well as in other states,” the senator, who was speaking at a hearing at which lawmakers approved a bill to legalize marijuana dispensary drive-thru windows in California, said. “I think it’s time for us to have a serious analysis of that, and whether or not we want to develop a proposition to go back to the voters and either reverse it or somehow reform it so that we don’t continually deal with the problems that we do.” “I oppose the legalization of marijuana,” he said, citing data about cannabis use by young people and an alleged link to mental health problems and claiming that the 2016 reform was “written to please everybody” which resulted in a “dysfunctional policy that is bound for unintended consequences.” Elsewhere in the U.S., marijuana legalization opponents are currently collecting signatures to put measures to roll back the reform in Maine and Massachusetts—though those anti-cannabis campaigns have faced accusations of misleading petitioning tactics. A separate anti-marijuana effort in Arizona for a similar measure was dropped after its lead organizer said his initial concerns about the legal cannabis industry were misplaced. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Back in California, regulators recently adopted emergency rules changes for the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent move to federally reschedule medical cannabis. They also separately launched a new AI tool to help businesses identify marijuana product packaging may appeal to kids in violation of state rules. Gov. Gavin Newsom (D), meanwhile, recently took credit for helping to lead the push for the state to legalize marijuana and discussed his own limited experience with using cannabis. In October, however, Newsom vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS, stating that the proposal “would be burdensome and overly complex to administer.” Newsom did sign a bill earlier that month aimed at streamlining research on marijuana and psychedelics. In September, the governor also signed a measure into law to put a pause on a recently enacted tax hike on marijuana products. Separately, the state attorney general says Indian tribes cannot independently engage in marijuana commerce with licensed cannabis businesses without first obtaining their own commercial license from state officials. California officials recently awarded nearly $30 million in grants for marijuana-focused academic research projects. The post California GOP Senator Suggests Putting Marijuana Back On The Ballot To ‘Reverse’ Legalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The new chair of the Cannabis Control Commission had previously led the state’s Cannabis Office. By Christopher Shea, Rhode Island Current The independent state agency shaping the nascent cannabis industry is whole again, with a new chairperson confirmed by the Rhode Island Senate on its final day of the legislative session. The chamber’s unanimous vote Thursday confirms Michelle Reddish as chair of the Cannabis Control Commission, filling the seat left open since October when former leader Kim Ahern resigned to run for attorney general. Reddish, who has led the state’s Cannabis Office since 2024, now transitions from operational duties to policymaking as chair of the commission. The $204,069 post is the only full-time position on the panel charged with regulating the state’s medical and recreational marijuana and hemp industries. Also Thursday, the Senate reappointed commissioner Robert Jacquard for a second term on the cannabis panel. Both Jacquard and Reddish will serve until May 17, 2031. This story was first published by Rhode Island Current. Unrelated content excised by Marijuana Moment. Photo courtesy of Chris Wallis // Side Pocket Images. The post Rhode Island Senate Confirms New Top Marijuana Regulator appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A federal science agency has added dozens of new marijuana components to an official government library of compounds that is used to help identify unknown substances in food, drugs, cosmetics, the environment, body fluids and forensic evidence. The National Institute of Standards and Technology (NIST) announced last week that the cannabis components were being added as part of a broader update to its library of mass spectra measured from hundreds of thousands of compounds, known formally as Standard Reference Database 1A. The minor cannabinoids, NIST said, are “trace chemicals hidden inside the cannabis plant that are being explored for medical uses, including pain relief.” In response to a query from Marijuana Moment, NIST officials specified that 41 new spectra related to cannabinoid compounds have been added in this update on top of the 80 that were already included in the library. “By introducing 41 new cannabinoid compounds to the NIST26 library—bringing the total to 121—this expanded collection continues to reflect a strategic selection of compounds that are of significant importance to numerous fields including forensics, biomedical research, food science and environmental chemistry,” NIST data scientist Tytus Mak, who selects the compounds that are added to the database, told Marijuana Moment. To build out the NIST Mass Spectral Library, scientists use a mass spectrometer to effectively generate chemical fingerprints for compounds. The device “ionizes and shatters a compound into charged fragments and then sorts those fragments by their mass-to-charge ratio,” the agency said. When researchers or product manufacturers find a compound of unknown identity, they can us their own mass spectrometry device and then compare the results to NIST’s library to find a match. “Just as a person may be identified by comparing their DNA to a database, a chemical compound may be identified by comparing its mass spectrum to the NIST database,” Bill Wallace, group leader of NIST’s Mass Spectrometry Data Center, said. Who you gonna call when you’re spooked by a mystery compound? NIST! NIST has updated its comprehensive list of chemical fingerprints, called mass spectra, that others rely on to identify unknown compounds in food, drugs, and even space rocks. https://t.co/9J0TJUj4yc pic.twitter.com/UzK7kXAJ3E — National Institute of Standards and Technology (@NIST) June 9, 2026 With respect to the new cannabis-related additions, a summary provided to Marijuana Moment by NIST says that its preexisting library was “excellent for identifying standard, classical cannabinoids and major human metabolites” but that the newly added compounds “fill a specific analytical gap.” “The most significant takeaway is that the new additions focus heavily on rare alkyl side-chain homologs and their analytical derivatives, expanding the library well beyond the standard cannabis compounds,” it said. “They provide the reference spectra needed to identify rare plant variants, degradation artifacts and minor homologs that are becoming increasingly relevant in modern cannabis testing.” The agency noted that it chooses which compounds to add to its library using outside databases and lists to understand which are broadly “important to chemists,” and that it “prioritizes those found on multiple lists.” The expansion of the cannabinoid portion of the libray focuses on adding rare side-chain homologs, abnormal and exo isomers, derivatives and epoxidation products. See below for the full list of compounds now in the NIST library, with asterisks next to new additions: .delta.-9-Tetrahydrocannabinoic acid a .DELTA.8-Tetrahydrocannabinol .DELTA.8-Tetrahydrocannabinol .DELTA.8-Tetrahydrocannabinol, TBDMS derivative @ .DELTA.8-Tetrahydrocannabivarin .DELTA.9-Tetrahydrocannabinol .DELTA.9-Tetrahydrocannabinol, TBDMS derivative @ .DELTA.9-Tetrahydrocannabinol, TMS derivative @ .DELTA.9-Tetrahydrocannabiorcol * .DELTA.9-Tetrahydrocannabiorcol, acetate * .DELTA.9-Tetrahydrocannabiorcol, methyl ether * .DELTA.9-Tetrahydrocannabiorcol, TMS * .delta.9-Tetrahydrocannabivarin .DELTA.11-Tetrahydrocannabinol (.+/-.)-.DELTA.9-Tetrahydrocannabinol (.+/-.)-11-Hydroxy-.DELTA.9-tetrahydrocannabinol (.+/-.)-11-Nor-.DELTA.9-tetrahydrocannabinol-9-carboxylic acid (.+/-.)-Cannabichromene (.+/-.)-Cannabicyclol (.+/-.)-Cannabicyclol, acetate (.+/-.)-Cannabicyclol, methyl ester (.+/-.)-Cannabicyclol, TMS (+)-11-Nor-.DELTA.9-tetrahydrocannabinol-9-carboxylic acid glucuronide 1′-Hydroxycannabinol 1′-Oxocannabinol 1(R),2(S)-Epoxy cannabidiol * 1(R),2(S)-epoxy Cannabidiol, dimethyl ether * 1(R),2(S)-Epoxy cannabidiol, O,O-diacetate- * 1(R),2(S)-epoxy Cannabidiol, TMS * 1(R),2(S)-Epoxycannabidiol * 11-Hydroxy-.DELTA.-9-tetrahydrocannabinol, bis(trimethylsilyl) ether 11-Hydroxy-.DELTA.-9-tetrahydrocannabinol, O,O’-bis(trifluoroacetyl)- 11-Hydroxy-.DELTA.-9-tetrahydrocannabinol, tert-butyldimethylsilyl derivative 11-Hydroxy-.DELTA.9-tetrahydrocannabinol 11-Hydroxy-.DELTA.9-tetrahydrocannabinol 11-Hydroxy-.DELTA.9-tetrahydrocannabinol, 2TBDMS derivative @ 11-Hydroxycannabinol 11-Nor-.delta.-9-tetrahydrocannabinol-9-carboxylic acid 11-Nor-9-carboxy-.DELTA.9-tetrahydrocannabinol 8.alpha.-Hydroxyhexahydrocannabinol, bis(trimethylsilyl) ether 8.beta.,11-Dihydroxy-.delta.-9-tetrahydrocannabinol Abnormal cannabidivarin * Abnormal cannabidivarin, 2TMS * Abnormal cannabidivarin, acetate * Abnormal cannabidivarin, diacetate * Abnormal cannabivarin, TMS Bis-trimethylsilyl-.delta.-9-tetrahydrocannabinol acid b Cannabibutol * Cannabibutol, acetate * Cannabibutol, methyl ether * Cannabibutol, TMS * Cannabichromene Cannabicitran Cannabicoumaronone Cannabidihexol * Cannabidiol Cannabidiol Cannabidiol dimethyl ether Cannabidiol-C8 * Cannabidiol-C8 * Cannabidiol-C8, 2TMS * Cannabidiol-C8, O,O-diacetate * Cannabidiol, 2Ac derivative Cannabidiol, 2TFA Cannabidiol, 2TMS derivative @ Cannabidiol, Ac derivative Cannabidiolic acid Cannabidiolic acid, 3TMS Cannabidiorocol Cannabidiphorol Cannabidivarin Cannabidivarin diacetate * Cannabidivarin, 2TMS Cannabidivarol Cannabigerohexol * Cannabigerol Cannabigerol dimethyl ether * Cannabigerol monomethyl ether * Cannabigerol monomethyl ether, TMS * Cannabigerorcin Cannabigerorcinic acid Cannabigerorcinic acid, 3TMS * Cannabigerorcinic acid, dimethyl ether, methyl ester Cannabigerovarin Cannabihexol * Cannabihexol, acetate * Cannabihexol, methyl ether * Cannabihexol, TMS * Cannabinol Cannabinol ethyl * Cannabinol ethyl, acetate * Cannabinol ethyl, methyl ether * Cannabinol ethyl, TMS * Cannabinol methyl derivative Cannabinol, acetate Cannabinol, heptafluorobutyrate Cannabinol, pentafluoropropionate Cannabinol, TBDMS derivative @ Cannabinol, TMS derivative @ Cannabinol, trifluoroacetate Cannabipiperidiethanone Cannabispiran Cannabivarin Cannabivarinselsoin * Cannabivarinselsoin, methyl ether * Deoxy Cannabidiol Eucannabinolide Eucannabinolide, 2TMS exo-Tetrahydrocannabivarin * exo-Tetrahydrocannabivarin, methyl ether * exo-Tetrahydrocannabivarin, TMS * Hexahydrocannabi-1,10.beta.diol Hexahydrocannabinol Hydroxy-.delta. 9-tetrahydrocannabinol, 8-.alpha. Hydroxy-.delta. 9-tetrahydrocannabinol, 8-.beta. Methyl 1-dehydroxy-1-methoxy-11-nor-.delta.-9-tetrahydrocannabinol-9-carboxylate Norcannabinol-9-carboxylic acid, 11- Tetrahydrocannabinolcarbonic acid-D3-HFBA-PFPOH-Derivative Tetrahydrocannabinolcarbonic acid-D9-HFBA-PFPOH-Derivative Tetrahydrocannabinolcarbonic acid-HFBA-PFPOH-Derivative Tetrahydrocannabivarin Note: Some compound names are repeated due to there being separate entries in the library for stereoisomers of the same compound. The post Federal Science Agency Adds New Cannabis Compounds To Its Library Of ‘Chemical Fingerprints’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Succeed! It could be one of the most useful blogs we have ever come across on the subject. Excellent info! I’m also an expert in this topic so I can understand your effort very well. Thanks for the huge help. dax69 alternatif

Marijuana rescheduling & interstate commerce; Drug scheduling bill in Congress; IL gov signs cannabis overhaul; Ukraine medical marijuana sales begin Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Virginia Gov. Abigail Spanberger (D) and legislative leaders “have a deal” to legalize recreational marijuana sales through the budget this month, a key lawmaker has announced. Illinois Gov. JB Pritzker (D) signed a large-scale cannabis omnibus bill into law that doubles the amount of marijuana that adults can legally possess, significantly restricts hemp THC products and makes other changes to rules for how licensed businesses can operate. Rep. Steve Cohen (D-TN) filed a bill to overhaul how drugs like marijuana, psychedelics and others are evaluated for scheduling under the Controlled Substances Act—for example by effectively letting states force federal reclassification by changing their own laws. The Marijuana Policy Project published an analysis of how “interstate commerce between licensed businesses would…be presumably federally legal” under the Trump administration’s cannabis rescheduling move. Ukraine’s Ministry of Health announced that the country’s medical cannabis program is officially operational, with the first THC products being dispensed to two military veterans and a woman with multiple sclerosis. The Massachusetts Supreme Judicial Court rejected a lawsuit challenging a proposed ballot measure to roll back marijuana legalization—ruling that it does not violate the state Constitution. New Hampshire Gov. Kelly Ayotte (R) vetoed a bill to allow medical cannabis businesses to cultivate in greenhouses, a reform intended to increase supply and lower prices for patients. The North Carolina House Agriculture and Environment Committee approved an amended bill to restrict hemp and kratom products to people over the age of 21. The Alabama Medical Cannabis Commission reported that more than 100 patients purchased marijuana products during the first week of legal sales in the state. / FEDERAL The Drug Enforcement Administration promoted an article claiming that marijuana use is linked to a 50 percent lower chance of graduating high school. Sen. Dick Durbin (D-IL) said in a Senate floor speech that “we have seen how outdated mandatory minimum policies stemming from the failed ‘War on Drugs’ continue to impose lengthy, one-size-fits- all sentences for many nonviolent drug offenses. They don’t deter crime; instead, they overcrowd prisons and strain budgets.” / STATES Kansas Democratic gubernatorial candidates discussed medical cannabis during a debate. The Oklahoma attorney general’s Organized Crime Task Force touted enforcement actions against allegedly illegal marijuana manufacturing operations. Pennsylvania’s Senate minority leader said the state’s medical cannabis program “should be used as a steppingstone to expand to adult and recreational use.” A Virginia senator criticized marijuana penalties that Gov. Abigail Spanberger (D) proposed adding to a recreational cannabis sales legalization bill. The Ohio Supreme Court is taking up conflicting cases on whether police can search vehicles based on the smell of marijuana. A federal judge rejected a request to block New York regulators from prioritizing marijuana business licenses for people with cannabis convictions within the state over those with convictions from elsewhere. California regulators announced a recall of marijuana products due to incomplete and incorrect regulatory compliance testing. Montana regulators sent guidance about updating marijuana exit packaging requirements. Washington, D.C. regulators are moving to deny a medical cannabis retailer license application due to the owner’s alleged involvement in illegal marijuana operations. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Missoula, Montana City Council’s Housing, Redevelopment and Community Programs Committee approved a proposal to extend a moratorium on new recreational marijuana dispensaries. The Sacramento, California City Council is expected to vote on a proposal to change marijuana business zoning rules this week. / INTERNATIONAL New Zealand officials adopted new rules increasing THC limits for hemp. / SCIENCE & HEALTH A study found that cannabis-based medicinal products “treatment was associated with sustained improvements in outcomes for individuals with hypermobility-associated chronic pain.” A study found that “close to one-quarter of US adults (23.0%) are estimated to either disagree or not know that addiction is a health condition.” / ADVOCACY, OPINION & ANALYSIS The Kentucky Democratic Party tweeted, “Governor Beshear knows that medical cannabis provides safe relief from pain and he delivered it for Kentuckians.” The president and CEO of American Trucking Associations testified at a Senate hearing that “full rescheduling of all marijuana products raises safety concerns by weakening employers’ zero-tolerance policies, compromising the current federal drug testing program for safety-sensitive professions, complicating enforcement, and potentially increasing marijuana use among all drivers.” / BUSINESS Trulieve Cannabis Corp.’s president resigned. Illinois dispensaries sold $13.8 million worth of medical cannabis products in May. / CULTURE Zac Efron is building a house in Australia that’s made mostly from hemp. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Virginia cannabis sales legalization deal reached (Newsletter: June 15, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I'm not the type to write reviews, but this experience changed my mind. I was a nervous first-timer, and the person on the phone could tell. They were patient, answered all my questions, and helped me choose someone who matched my energy. When I booked a Kolkata Call Girl, she arrived on time near the College Street coffee house, looked even better than her photos, and within five minutes, my nerves disappeared. We laughed, we talked, and the evening felt completely natural. If you're hesitating like I was, take the leap in the City of Joy.

Categories despite issues occasionally our Lucknow Call Girl Service vibrant sensation remained individuals significantly fewer ice and one outcome is, shape Anand in previous error community are and fresh life beginning of introducing and revitalized is undertaking is happening.

Hello. As a game software developer, I enjoy entertaining with diverse genres. Recent favourite games include geometry dash subzero. Rapid-paced game that lets me explore vivid colours.

“Our store manager saw a patient walking out, and as silly as it sounds, they jumped and clicked their heels. Yeah, they were that happy about having that medicine.” By Anna Barrett, Alabama Reflector Over 100 qualifying patients have purchased medical cannabis since Alabama’s first dispensary opened, the Alabama Medical Cannabis Commission said Thursday. The state’s first legal medical cannabis provider, Callie’s Apothecary, opened its first location in Montgomery on June 4 following a “soft opening” the day before. Justin Aday, general counsel for the commission, said Thursday that 102 patients have purchased medical cannabis products in 111 transactions. Those transactions have generated about $14,600 in pre-tax sales with the average transaction being $131.56, Aday said. Vince Schilleci, owner of Callie’s, said in a phone interview Thursday afternoon that the last week of business has been rewarding. “I’m seeing a lot of happy patients,” he said. “Our store manager saw a patient walking out, and as silly as it sounds, they jumped and clicked their heels. Yeah, they were that happy about having that medicine.” According to the patient menu on Callie’s website, each product ranges from $42 to $52 each. Schilleci said that the dispensary got its second shipment of products on Thursday and expects another one on Friday, which will help meet the demand of patients. “We’ve had to—I hate to use this term ration—but we’ve limited how much patients could purchase, just because we knew how many patients were coming on board, and we at least wanted people to have a chance to have something,” Schilleci said. “We’ve lifted the rationing now, so patients can come down and buy their full 60-day allotment if they choose.” Aday said that as of Thursday morning, 481 patients have applied for a cannabis card and 446 of them have been issued one by the AMCC. The Alabama medical cannabis law, enacted in 2021, allows registered physicians to recommend cannabis for about 15 medical conditions, including cancer, depression, Parkinson’s Disease, PTSD, sickle-cell anemia, chronic pain and terminal diseases. The approved product forms are restricted to tablets, tinctures, patches, oils and gel cubes (only peach flavor), with raw plant material and smokable forms remaining prohibited. As of Thursday, there are 52 physicians certified to recommend medical cannabis to patients in Alabama, according to the Alabama Board of Medical Examiners. Aday said 39 are registered with the AMCC, with three pending, and 21 of the physicians have made medical cannabis recommendations to patients. “We’re certainly looking forward to more of these patients being able to get to that dispensary and seeing other dispensaries open that will provide more geographic coverage for them,” Aday said. “We’re working diligently with processors in the lab on new products that are being manufactured so that the dispensary can maintain an inventory of products and a variety of products in that inventory to serve the patients that are visiting them.” Litigation has also held up access to medical cannabis. Some firms sued the commission for not being awarded a license, citing a discriminatory process. Another case involved five parents that sued the commission over delays in access to cannabis, which was dismissed in August. Licenses for three of the four possible dispensary companies were not approved until December. Three of the companies, CCS of Alabama, LLC, GP6 Wellness, LLC and RJK Holdings, LLC, have licenses and are expected to open their storefronts this summer, according to AMCC Director John McMillan. A fourth license is pending litigation, but is likely to go to Yellowhammer Medical Dispensaries, LLC. “I would do it again just to see the smile on these patients’ faces. Now, I would hope a little bit easier, but it’s been worth it,” Schilleci said. “It’s been worth it. There’s no doubt.” This story was first published by Alabama Reflector. Photo courtesy of Max Pixel. The post More Than 100 Alabama Patients Bought Medical Marijuana In First Week Of Legal Sales appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. AK 게임

Thanks for taking the time to discuss this, I feel strongly about it and love learning more on this topic. If possible, as you gain expertise, would you mind updating your blog with extra information? It is extremely helpful for me. 모바일섯다

I read that Post and got it fine and informative. 온라인홀덤

I definitely enjoying every little bit of it. It is a great website and nice share. I want to thank you. Good job! You guys do a great blog, and have some great contents. Keep up the good work. Slot Thailand

What a fantabulous post this has been. Never seen this kind of useful post. I am grateful to you and expect more number of posts like these. Thank you very much. Jadwal Bola Malam Ini

Nice post! This is a very nice blog that I will definitively come back to more times this year! Thanks for informative post. Lapak303 Poker

“There are a lot of other details surrounding cannabis that have been discussed and will continue to be discussed.” By Christine Zhu, NC Newsline North Carolina lawmakers are considering banning individuals under 21 from buying or possessing certain hemp-derived consumable products, including smokable hemp flower, hemp cigarettes, gummies and beverages, or any items that include the drug kratom. The House Agriculture and Environment Committee approved a rewrite of Senate Bill 59 on Wednesday. It’s the latest attempt by state lawmakers to regulate the sale of hemp products after years of proposals that ultimately didn’t succeed. The measure would prohibit businesses from selling these products to those under 21. If a seller has “reasonable grounds” to believe the prospective buyer is under 21, the seller must check the buyer’s ID. Rep. Jimmy Dixon (R-Duplin), who presented the bill, said he was motivated to draw public attention to issues surrounding cannabis. He said there was a 14-year-old in his district who wound up in the emergency room after purchasing a hemp-derived product. “There are a lot of other details surrounding cannabis that have been discussed and will continue to be discussed, but ladies and gentlemen, to be sure we’ve got the good sense to be an agent on these types of problems, that is the lowest hanging fruit there is,” he said. Those found in violation of the measure would face a Class 2 misdemeanor as well as a $500 fine for a first offense, $1,000 for a second offense and $1,500 for subsequent offenses. Rep. Pricey Harrison (D-Guilford) asked if the bill’s language accounted for potential modifications to hemp-derived products. It’s common for makers of synthetic recreational drugs to make changes to their products’ chemical makeup to get around legal bans or restrictions. “I assume the way the definition is as written is broad enough that it captures any future manipulation of molecules,” she said. Dixon nodded in the affirmative. Legislators also voted in favor of an amendment to add kratom products to the under-21 ban. Rep. Jeffrey McNeely (R-Iredell), who proposed the amendment, said he felt it was necessary to add those items to the bill. “I’ve worked on this for quite a while now, trying to put forth these bills,” McNeely said. “We’ve definitely got a problem. So I hope we keep bringing this to light, and we get something accomplished before we get out of short session here.” Both the amendment and the legislation passed unanimously without debate. The bill moves next to the House Rules Committee. Other amendments will be heard when it appears on the House floor, which could be as soon as next week. This story was first published by NC Newsline. The post North Carolina Lawmakers Advance Bill To Set A Minimum Age Limit For Hemp And Kratom Products appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Document thrilled along with the researching you will designed to makes precise put up impressive. Delightful adventure! 인디고 게임

A detailed and reader-friendly post with clear explanations. The step-by-step presentation makes it easier to understand. While researching Escorts in Delhi, your blog provided helpful and practical guidance.

“I do not support expanding the cultivation of marijuana in our state.” By William Skipworth, New Hampshire Bulletin Gov. Kelly Ayotte (R) quashed a bipartisan effort to make medicinal marijuana more affordable and available in New Hampshire. Senate Bill 468, sponsored by Loudon Republican Sen. Howard Pearl, would allow medicinal marijuana dispensaries to have their own greenhouse on site. The idea is to increase supply and lower prices. Each dispensary would be limited to one greenhouse to grow their own cannabis. Ayotte vetoed the bill on Friday. “I do not support expanding the cultivation of marijuana in our state,” she wrote in her veto statement. “For this reason, I have vetoed SB 468.” New Hampshire legalized marijuana for medical use in 2013 while Maggie Hassan was governor. The law limits people to two ounces of marijuana and allows only a designated group of providers. The only dispensaries in the state are in Chichester, Conway, Dover, Keene, Lebanon, Merrimack and Plymouth, and they’re all operated by one of four nonprofit “alternative treatment centers.” New Hampshire residents need a medical marijuana card issued by a physician to shop at any of them. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — New Hampshire is the only New England state that hasn’t legalized recreational marijuana. Nationwide, 24 states have legalized the drug for recreational purposes and 39 for medical use. Ayotte has repeatedly opposed recreational legalization in New Hampshire, citing multiple factors. She’s worried about the fact that police are unable to measure a driver’s level of marijuana intoxication using current technology like they can with alcohol. She has also cited youth mental health and “quality of life.” It would take a two-thirds vote in both the House and Senate to override Ayotte’s veto. The Legislature will meet later this year to vote on whether to do so. This story was first published by New Hampshire Bulletin. Unrelated context excised by Marijuana Moment. Photo courtesy of Chris Wallis // Side Pocket Images. The post New Hampshire Governor Vetoes Bill To Allow Medical Marijuana Cultivation In Greenhouses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

That i taken aback when using the exploration everyone intended to get this to selected present astounding. Terrific process! AK 게임

It is my first visit to your blog, and I am very impressed with the articles that you serve. Give adequate knowledge for me. Thank you for sharing useful material. I will be back for the more great post. situs toto